Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1986 Sep;83(18):7059–7063. doi: 10.1073/pnas.83.18.7059

Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

I Hellström, P L Beaumier, K E Hellström
PMCID: PMC386652  PMID: 3462743

Abstract

Mouse monoclonal antibody L6 (IgG2a subtype) recognizes a ganglioside antigen expressed at the surface of cells from human non-small-cell lung carcinomas, breast carcinomas, and colon carcinomas. We now show that this antibody can lyse L6 antigen-positive human tumor cells in the presence of Leu-11b-positive human lymphocytes (i.e., mediate antibody-dependent cellular cytotoxicity) or human serum (mediate complement-dependent cytotoxicity) and that it can inhibit the outgrowth of an L6 antigen-positive human tumor transplanted onto nude mice.

Full text

PDF
7059

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaumier P. L., Neuzil D., Yang H. M., Noll E. A., Kishore R., Eary J. F., Krohn K. A., Nelp W. B., Hellström K. E., Hellström I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med. 1986 Jun;27(6):824–828. [PubMed] [Google Scholar]
  2. Garrigues H. J., Tilgen W., Hellstróm I., Franke W., Hellström K. E. Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer. 1982 May 15;29(5):511–515. doi: 10.1002/ijc.2910290505. [DOI] [PubMed] [Google Scholar]
  3. Hellström I., Brankovan V., Hellström K. E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1499–1502. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hellström I., Hellström K. E., Yeh M. Y. Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas. Int J Cancer. 1981 Mar 15;27(3):281–285. doi: 10.1002/ijc.2910270305. [DOI] [PubMed] [Google Scholar]
  5. Hellström I., Horn D., Linsley P., Brown J. P., Brankovan V., Hellström K. E. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986 Aug;46(8):3917–3923. [PubMed] [Google Scholar]
  6. Houghton A. N., Mintzer D., Cordon-Cardo C., Welt S., Fliegel B., Vadhan S., Carswell E., Melamed M. R., Oettgen H. F., Old L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242–1246. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Koprowski H., Herlyn D., Lubeck M., DeFreitas E., Sears H. F. Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A. 1984 Jan;81(1):216–219. doi: 10.1073/pnas.81.1.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Martin P. J., Longton G., Ledbetter J. A., Newman W., Braun M. P., Beatty P. G., Hansen J. A. Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol. 1983 Jul;131(1):180–185. [PubMed] [Google Scholar]
  9. Sears H. F., Atkinson B., Mattis J., Ernst C., Herlyn D., Steplewski Z., Häyry P., Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982 Apr 3;1(8275):762–765. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES